JP2012518038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012518038A5 JP2012518038A5 JP2011551161A JP2011551161A JP2012518038A5 JP 2012518038 A5 JP2012518038 A5 JP 2012518038A5 JP 2011551161 A JP2011551161 A JP 2011551161A JP 2011551161 A JP2011551161 A JP 2011551161A JP 2012518038 A5 JP2012518038 A5 JP 2012518038A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- disease
- tert
- amide
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 137
- 229910052736 halogen Chemical group 0.000 claims description 66
- 150000002367 halogens Chemical group 0.000 claims description 66
- 150000001875 compounds Chemical class 0.000 claims description 36
- -1 6 - thiomorpholinyl Chemical group 0.000 claims description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
- 125000004076 pyridyl group Chemical group 0.000 claims description 18
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 14
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 125000002757 morpholinyl group Chemical group 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- GGXGVZJHUKEJHO-UHFFFAOYSA-N 5-tert-butyl-1,2-oxazol-3-amine Chemical compound CC(C)(C)C1=CC(N)=NO1 GGXGVZJHUKEJHO-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- FGFUOQTXKVUZTE-CQSZACIVSA-N (3r)-n-(5-tert-butyl-1,2-oxazol-3-yl)-1-(4,4-difluorocyclohexanecarbonyl)piperidine-3-carboxamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)[C@H]2CN(CCC2)C(=O)C2CCC(F)(F)CC2)=N1 FGFUOQTXKVUZTE-CQSZACIVSA-N 0.000 claims 1
- FGFUOQTXKVUZTE-AWEZNQCLSA-N (3s)-n-(5-tert-butyl-1,2-oxazol-3-yl)-1-(4,4-difluorocyclohexanecarbonyl)piperidine-3-carboxamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)[C@@H]2CN(CCC2)C(=O)C2CCC(F)(F)CC2)=N1 FGFUOQTXKVUZTE-AWEZNQCLSA-N 0.000 claims 1
- RZGUAQHPDVTBPX-UHFFFAOYSA-N 1-[5-(trifluoromethyl)pyridin-1-ium-2-yl]piperidine-3-carboxylate Chemical compound C1C(C(=O)O)CCCN1C1=CC=C(C(F)(F)F)C=N1 RZGUAQHPDVTBPX-UHFFFAOYSA-N 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000002881 Colic Diseases 0.000 claims 1
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 1
- 206010051606 Necrotising colitis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010046823 Uterine spasm Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000030172 endocrine system disease Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000017445 musculoskeletal system disease Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- UHAZEEBEVPEHEB-UHFFFAOYSA-N n-(5-tert-butyl-1,2-oxazol-3-yl)-1-(1,1-dioxo-1,4-thiazinane-4-carbonyl)piperidine-3-carboxamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)C2CN(CCC2)C(=O)N2CCS(=O)(=O)CC2)=N1 UHAZEEBEVPEHEB-UHFFFAOYSA-N 0.000 claims 1
- FGFUOQTXKVUZTE-UHFFFAOYSA-N n-(5-tert-butyl-1,2-oxazol-3-yl)-1-(4,4-difluorocyclohexanecarbonyl)piperidine-3-carboxamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)C2CN(CCC2)C(=O)C2CCC(F)(F)CC2)=N1 FGFUOQTXKVUZTE-UHFFFAOYSA-N 0.000 claims 1
- NCMIJNDQYXAACE-UHFFFAOYSA-N n-(5-tert-butyl-1,2-oxazol-3-yl)-1-(4-chlorophenyl)sulfonylpiperidine-3-carboxamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)C2CN(CCC2)S(=O)(=O)C=2C=CC(Cl)=CC=2)=N1 NCMIJNDQYXAACE-UHFFFAOYSA-N 0.000 claims 1
- XUFOBANCAUFBEO-UHFFFAOYSA-N n-(5-tert-butyl-1,2-oxazol-3-yl)-1-(morpholine-4-carbonyl)piperidine-3-carboxamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)C2CN(CCC2)C(=O)N2CCOCC2)=N1 XUFOBANCAUFBEO-UHFFFAOYSA-N 0.000 claims 1
- ITJWXYCRTHWDND-UHFFFAOYSA-N n-(5-tert-butyl-1,2-oxazol-3-yl)-1-(oxane-4-carbonyl)piperidine-3-carboxamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)C2CN(CCC2)C(=O)C2CCOCC2)=N1 ITJWXYCRTHWDND-UHFFFAOYSA-N 0.000 claims 1
- JLPIGMUIUQSGDW-UHFFFAOYSA-N n-(5-tert-butyl-1,2-oxazol-3-yl)-1-[(4-chlorophenyl)methyl]piperidine-3-carboxamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)C2CN(CC=3C=CC(Cl)=CC=3)CCC2)=N1 JLPIGMUIUQSGDW-UHFFFAOYSA-N 0.000 claims 1
- PVYVYDAJEHDNCZ-UHFFFAOYSA-N n-(5-tert-butyl-1,2-oxazol-3-yl)-1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperidine-3-carboxamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)C2CN(CCC2)C=2C(=CC(=CN=2)C(F)(F)F)Cl)=N1 PVYVYDAJEHDNCZ-UHFFFAOYSA-N 0.000 claims 1
- RXTDALHZFGECBA-UHFFFAOYSA-N n-(5-tert-butyl-1,2-oxazol-3-yl)-1-[4-(trifluoromethyl)benzoyl]piperidine-3-carboxamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)C2CN(CCC2)C(=O)C=2C=CC(=CC=2)C(F)(F)F)=N1 RXTDALHZFGECBA-UHFFFAOYSA-N 0.000 claims 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 description 24
- 125000000623 heterocyclic group Chemical group 0.000 description 18
- 125000004043 oxo group Chemical group O=* 0.000 description 16
- 125000001072 heteroaryl group Chemical group 0.000 description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 13
- 125000000842 isoxazolyl group Chemical group 0.000 description 12
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 9
- 125000002971 oxazolyl group Chemical group 0.000 description 7
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 7
- 125000002252 acyl group Chemical group 0.000 description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 6
- 125000003373 pyrazinyl group Chemical group 0.000 description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 125000001786 isothiazolyl group Chemical group 0.000 description 4
- 125000004193 piperazinyl group Chemical group 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 125000002098 pyridazinyl group Chemical group 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 4
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 description 4
- BUGOPWGPQGYYGR-UHFFFAOYSA-N thiane 1,1-dioxide Chemical compound O=S1(=O)CCCCC1 BUGOPWGPQGYYGR-UHFFFAOYSA-N 0.000 description 4
- 125000004306 triazinyl group Chemical group 0.000 description 4
- 125000001425 triazolyl group Chemical group 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000000532 dioxanyl group Chemical group 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 0 **(CCC1)CN(*)C1C(N*)=O Chemical compound **(CCC1)CN(*)C1C(N*)=O 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15333309P | 2009-02-18 | 2009-02-18 | |
| US61/153,333 | 2009-02-18 | ||
| PCT/US2010/024270 WO2010096371A2 (en) | 2009-02-18 | 2010-02-16 | Heterocyclic compounds which modulate the cb2 receptor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012518038A JP2012518038A (ja) | 2012-08-09 |
| JP2012518038A5 true JP2012518038A5 (cg-RX-API-DMAC10.html) | 2014-09-18 |
| JP5705748B2 JP5705748B2 (ja) | 2015-04-22 |
Family
ID=42154367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011551161A Active JP5705748B2 (ja) | 2009-02-18 | 2010-02-16 | Ｃｂ２受容体を変調する複素環化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8889670B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2398771B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP5705748B2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2010096371A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008014199A2 (en) | 2006-07-28 | 2008-01-31 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the cb2 receptor |
| KR20090069318A (ko) | 2006-09-25 | 2009-06-30 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｃｂ2 수용체를 조절하는 화합물 |
| WO2008048914A1 (en) | 2006-10-17 | 2008-04-24 | Boehringer Ingelheim International Gmbh | Polycyclic compounds which modulate the cb2 receptor |
| US8173638B2 (en) | 2006-11-21 | 2012-05-08 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
| EP2217565B1 (en) * | 2007-11-07 | 2013-05-22 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
| US8957063B2 (en) | 2008-02-21 | 2015-02-17 | Boehringer Ingelheim International Gmbh | Amine and ether compounds which modulate the CB2 receptor |
| EP2326629B1 (en) * | 2008-07-10 | 2013-10-02 | Boehringer Ingelheim International GmbH | Sulfone compounds which modulate the cb2 receptor |
| CA2737645A1 (en) | 2008-09-25 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the cb2 receptor |
| US8629157B2 (en) | 2009-01-05 | 2014-01-14 | Boehringer Ingelheim International Gmbh | Pyrrolidine compounds which modulate the CB2 receptor |
| EP2398771B1 (en) | 2009-02-18 | 2015-07-29 | Boehringer Ingelheim International GmbH | Heterocyclic compounds which modulate the cb2 receptor |
| US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| WO2010147791A1 (en) | 2009-06-16 | 2010-12-23 | Boehringer Ingelheim International Gmbh | Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor |
| EP2480544A1 (en) | 2009-09-22 | 2012-08-01 | Boehringer Ingelheim International GmbH | Compounds which selectively modulate the cb2 receptor |
| EP2523936A1 (en) | 2010-01-15 | 2012-11-21 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
| US8329735B2 (en) | 2010-03-05 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the CB2 receptor |
| WO2012012307A1 (en) | 2010-07-22 | 2012-01-26 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the cb2 rece |
| WO2012090177A2 (en) | 2010-12-30 | 2012-07-05 | Lupin Limited | Cannabinoid receptor modulators |
| WO2012090179A2 (en) | 2010-12-30 | 2012-07-05 | Lupin Limited | Isoquinoline derivatives as cannabinoid receptor modulators |
| WO2013005168A2 (en) | 2011-07-05 | 2013-01-10 | Lupin Limited | Cannabinoid receptor modulators |
| US20150065717A1 (en) | 2012-03-29 | 2015-03-05 | Toray Industries, Inc. | Nipecotic acid derivative and use thereof for medical purposes |
| EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| KR101823488B1 (ko) | 2013-10-14 | 2018-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 선택적으로 치환된 퀴놀린 화합물 |
| ES2670550T3 (es) | 2013-10-14 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Derivados de quinolina selectivamente sustituidos |
| GB201401886D0 (en) | 2014-02-04 | 2014-03-19 | Lytix Biopharma As | Neurodegenerative therapies |
| KR101555033B1 (ko) * | 2014-07-28 | 2015-09-23 | 충남대학교산학협력단 | 신규한 메타논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물 |
| TWI691486B (zh) | 2016-01-29 | 2020-04-21 | 日商東麗股份有限公司 | 環狀胺衍生物及其醫藥用途 |
| CN108218846A (zh) * | 2016-12-22 | 2018-06-29 | 四川海思科制药有限公司 | 噻吩衍生物的新固态形式及其制备方法和用途 |
| WO2019022235A1 (ja) | 2017-07-27 | 2019-01-31 | 東レ株式会社 | 円形脱毛症の治療剤又は予防剤 |
| TW201920137A (zh) * | 2017-08-31 | 2019-06-01 | 日商東麗股份有限公司 | 環狀胺衍生物及其醫藥用途 |
| WO2019046668A1 (en) * | 2017-08-31 | 2019-03-07 | Kezar Life Sciences | AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN |
| EP4157839A4 (en) * | 2020-05-29 | 2024-07-10 | Mayo Foundation for Medical Education and Research | Enhancers of particulate guanylyl cyclase receptor a |
| WO2023010051A1 (en) * | 2021-07-27 | 2023-02-02 | Gate Bioscience, Inc. | Protein secretion inhibitors |
| US20250026746A1 (en) * | 2021-11-23 | 2025-01-23 | Mayo Foundation For Medical Education And Research | Enhancers of particulate guanylyl cyclase receptor a |
| EP4695236A1 (en) * | 2023-04-14 | 2026-02-18 | Soley Therapeutics, Inc. | Substituted phenyl-piperazinyl based modulators for the treatment of disease |
| WO2024233501A2 (en) * | 2023-05-05 | 2024-11-14 | Allorock, Inc. | Therapeutic compounds |
| WO2026054614A1 (ko) * | 2024-09-09 | 2026-03-12 | 현대약품 주식회사 | 신규한 화합물, 및 이를 포함하는 약학적 조성물 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1237126A (en) | 1968-04-10 | 1971-06-30 | Agfa Gevaert Nv | 3-acyl-amino-pyrazolin-5-ones |
| JPH0680054B2 (ja) * | 1985-06-19 | 1994-10-12 | 吉富製薬株式会社 | ピペリジン誘導体 |
| DE3600950A1 (de) | 1986-01-15 | 1987-07-16 | Bayer Ag | 5-acylamido-1-aryl-pyrazole |
| DE3636278A1 (de) * | 1986-10-24 | 1988-05-05 | Hoechst Ag | Herbizide mittel auf der basis von cyclischen (alpha)-iminocarbon-saeureaniliden sowie neue (alpha)-iminocarbonsaeureanilide und verfahren zu ihrer herstellung |
| US5834490A (en) * | 1993-11-04 | 1998-11-10 | Instituto De Investigacion Y Desarrolo Quimico Biologico, S.A. | Cyclopropyl derivatives, preparation method there-of and applications |
| US5491170A (en) | 1994-12-19 | 1996-02-13 | Warner-Lambert Company | β-carboxy sulfonamide ACAT inhibitors |
| CN1104428C (zh) | 1996-09-13 | 2003-04-02 | 先灵公司 | 用作法呢基－蛋白转移酶抑制剂的取代的苯并芳庚并吡啶 |
| US5958940A (en) | 1997-09-11 | 1999-09-28 | Schering Corporation | Tricyclic compounds useful as inhibitors of farnesyl-protein transferase |
| US6337347B1 (en) | 1998-06-18 | 2002-01-08 | The Research & Development Institute, Inc. | Autoinducer compounds |
| US6756404B2 (en) | 1998-06-18 | 2004-06-29 | The Research & Development Institute, Inc. | Autoinducer compounds |
| WO2000008015A2 (en) | 1998-08-07 | 2000-02-17 | Applied Research Systems Ars Holding N.V. | Fsh mimetics for the treatment of infertility |
| CA2413313C (en) | 2000-06-23 | 2011-06-14 | Mitsubishi Pharma Corporation | Antitumor effect potentiators |
| WO2002088089A1 (en) | 2001-04-19 | 2002-11-07 | Banyu Pharmaceutical Co., Ltd. | Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions |
| JP2005530701A (ja) | 2002-03-05 | 2005-10-13 | バイエル・クロップサイエンス・ソシエテ・アノニム | 農薬としての５−置換アルキルアミノピラゾール誘導体 |
| CN1691944A (zh) | 2002-08-09 | 2005-11-02 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体－5调节剂的噁二唑 |
| AU2003264018A1 (en) | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| HRP20050053A2 (en) | 2002-09-19 | 2005-04-30 | Solvay Pharmaceuticals B.V. | 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands |
| OA12937A (en) | 2002-10-09 | 2006-10-13 | Pfizer Prod Inc | Thiazole compounds for the treatment of neurodegenerative disorders. |
| WO2004042351A2 (en) | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity |
| DE10307845A1 (de) | 2003-02-25 | 2004-09-02 | Bayer Cropscience Gmbh | Heterocyclische Amide, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel |
| MXPA05012196A (es) | 2003-05-12 | 2006-02-08 | Pfizer Prod Inc | Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos. |
| BRPI0413709A (pt) | 2003-08-21 | 2006-10-17 | Pfizer Prod Inc | compostos para o tratamento de distúrbios neurodegenerativos |
| EP1664010A1 (en) * | 2003-08-29 | 2006-06-07 | Vernalis (R&D) Limited | Sulfonamides antagonising n-type calcium channels |
| GB0325956D0 (en) * | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| AP2379A (en) | 2004-03-23 | 2012-03-08 | Pfizer Prod Inc | Imidazole compounds for the treatment of neurodegenerative disorders. |
| US7232820B2 (en) | 2004-04-01 | 2007-06-19 | Pfizer Inc | Thiadiazole-amine compounds for the treatment of neurodegenerative disorders |
| US20060009491A1 (en) | 2004-06-24 | 2006-01-12 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| US8019436B2 (en) | 2004-06-25 | 2011-09-13 | Cochlear Limited | Electrode assembly for a stimulating medical device |
| CN101014578B (zh) | 2004-09-16 | 2011-01-19 | 安斯泰来制药有限公司 | 三唑衍生物或其盐 |
| JP2006143667A (ja) * | 2004-11-22 | 2006-06-08 | Ube Ind Ltd | ピペコリン酸アミド誘導体及び抗菌剤 |
| US8084451B2 (en) | 2005-01-10 | 2011-12-27 | University Of Connecticut | Heteropyrrole analogs acting on cannabinoid receptors |
| CA2632030A1 (en) | 2005-12-15 | 2007-06-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| JP2009536613A (ja) | 2006-04-07 | 2009-10-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節する化合物 |
| BRPI0712720A2 (pt) | 2006-05-31 | 2012-11-20 | Abbott Lab | compostos tiazàis como ligantes do receptor canabinàide e usos dos mesmos |
| WO2008014199A2 (en) | 2006-07-28 | 2008-01-31 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the cb2 receptor |
| KR20090069318A (ko) | 2006-09-25 | 2009-06-30 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｃｂ2 수용체를 조절하는 화합물 |
| WO2008048914A1 (en) | 2006-10-17 | 2008-04-24 | Boehringer Ingelheim International Gmbh | Polycyclic compounds which modulate the cb2 receptor |
| US8173638B2 (en) | 2006-11-21 | 2012-05-08 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
| WO2008098025A1 (en) | 2007-02-08 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Arylsulfonamide compounds which modulate the cb2 receptor |
| CA2702772A1 (en) | 2007-10-25 | 2009-04-30 | Boehringer Ingelheim International Gmbh | Diazepane compounds which modulate the cb2 receptor |
| EP2217565B1 (en) | 2007-11-07 | 2013-05-22 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US8957063B2 (en) | 2008-02-21 | 2015-02-17 | Boehringer Ingelheim International Gmbh | Amine and ether compounds which modulate the CB2 receptor |
| US20120015988A1 (en) | 2008-05-13 | 2012-01-19 | Boehringer Ingelheim International Gmbh | Sulfone Compounds Which Modulate The CB2 Receptor |
| EP2326629B1 (en) | 2008-07-10 | 2013-10-02 | Boehringer Ingelheim International GmbH | Sulfone compounds which modulate the cb2 receptor |
| CA2737645A1 (en) | 2008-09-25 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the cb2 receptor |
| US8629157B2 (en) | 2009-01-05 | 2014-01-14 | Boehringer Ingelheim International Gmbh | Pyrrolidine compounds which modulate the CB2 receptor |
| EP2398771B1 (en) | 2009-02-18 | 2015-07-29 | Boehringer Ingelheim International GmbH | Heterocyclic compounds which modulate the cb2 receptor |
| US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| WO2010147791A1 (en) | 2009-06-16 | 2010-12-23 | Boehringer Ingelheim International Gmbh | Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor |
| NZ598269A (en) | 2009-09-18 | 2014-12-24 | Zalicus Pharmaceuticals Ltd | Aryl sulphone derivatives as calcium channel blockers |
| EP2480544A1 (en) | 2009-09-22 | 2012-08-01 | Boehringer Ingelheim International GmbH | Compounds which selectively modulate the cb2 receptor |
| EP2523936A1 (en) | 2010-01-15 | 2012-11-21 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
| US8329735B2 (en) | 2010-03-05 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the CB2 receptor |
| WO2012012307A1 (en) | 2010-07-22 | 2012-01-26 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the cb2 rece |
-
2010
- 2010-02-16 EP EP10704712.8A patent/EP2398771B1/en active Active
- 2010-02-16 WO PCT/US2010/024270 patent/WO2010096371A2/en not_active Ceased
- 2010-02-16 JP JP2011551161A patent/JP5705748B2/ja active Active
- 2010-02-16 US US13/147,432 patent/US8889670B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2548131T3 (es) | Sales farmacéuticamente aceptables de 2-{4-[(3S)-piperidin-3-il]fenil}-2H-indazol-7-carboxamida | |
| US11420934B2 (en) | PPAR agonists | |
| JP2012530137A5 (cg-RX-API-DMAC10.html) | ||
| AU2022329230A1 (en) | Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine | |
| AU2008334444B2 (en) | Peptidyl nitriles and use thereof as dipeptidyl peptidase I inhibitors | |
| ES2244231T3 (es) | Derivados de aminopirazol. | |
| JP2015529229A5 (cg-RX-API-DMAC10.html) | ||
| ES2362214T3 (es) | Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp). | |
| EP1402900A1 (en) | Medicinal compositions | |
| JP6276760B2 (ja) | ４−アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬 | |
| CA2436739A1 (en) | Combination agent | |
| RS58936B1 (sr) | Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp) | |
| WO2014145023A1 (en) | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities | |
| RU2013123275A (ru) | Пиперидин-4-илазетидиндиамиды как ингибиторы моноацилглицеринлипазы | |
| JP2020521767A5 (cg-RX-API-DMAC10.html) | ||
| JP2012224649A5 (cg-RX-API-DMAC10.html) | ||
| JP2010509242A5 (cg-RX-API-DMAC10.html) | ||
| JP2006524222A5 (cg-RX-API-DMAC10.html) | ||
| CA2431160A1 (en) | Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto | |
| MX2011004490A (es) | Moduladores de cxcr7. | |
| JP2003532730A (ja) | 細胞増殖抑制剤として有用な１，１−ジオキソイソチアゾリジンを持つインダゾール | |
| CA2825172A1 (en) | Indole derivative and pharmacologically acceptable salt of same | |
| CN106573908A (zh) | 羧酸化合物及其制备方法和用途 | |
| WO2014017093A1 (ja) | ベンゼン環縮合含窒素５員複素環式化合物、またはその薬理学的に許容される塩 | |
| AR078321A1 (es) | Derivados de 2,4'-bipiridina como inhibidores de cinasa (cdk9) |